Results 11 to 20 of about 1,302,201 (345)

Prostatitis [PDF]

Canadian Urological Association Journal, 2001
Prostatitis is a common condition that accounts for a significant number of visits to both the emergency department and the urologist. The precise pathogenic mechanism of prostatitis is not known. The most prevalent theory is that reflux of urine from the urethra into the intraprostatic ducts promotes ascending infection and leads to chemical or ...
W E, Lummus, I, Thompson
  +9 more sources

Prostatitis [PDF]

Hospital Medicine, 1999
Prostatitis, especially chronic prostatitis, is sometimes regarded as an obscure, ill-defined condition, perhaps because the anatomical location of the gland and ill-defined symptoms make diagnosis difficult. Treatment may appear time consuming and tiresome for doctor and patient, but by following established principles, diagnosis is often simple and ...
Ch, Theodorou, Th, Becopoulos
openaire   +4 more sources

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer

BMC Urology, 2023
Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...
Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson   +13 more
doaj   +1 more source

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma

Neoplasia: An International Journal for Oncology Research, 2015
Vascular endothelial growth factor (VEGF)–targeted antiangiogenic therapy significantly inhibits the growth of clear cell renal cell carcinoma (RCC).
Kyung Seok Han, Peter A. Raven, Sebastian Frees, Kilian Gust, Ladan Fazli, Susan Ettinger, Sung Joon Hong, Cristian Kollmannsberger, Martin E. Gleave, Alan I. So   +9 more
doaj   +1 more source

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease.
E. Schaeffer, S. Srinivas, E. Antonarakis, A. Armstrong, J. Bekelman, Heather H. Cheng, A. D'Amico, B. Davis, N. Desai, T. Dorff, J. Eastham, T. Farrington, Xin Gao, E. Horwitz, J. Ippolito, M. Kuettel, J. Lang, R. McKay, J. McKenney, G. Netto, D. Penson, J. Pow-Sang, R. Reiter, Sylvia S. Richey, Mack Roach Iii, Stan Rosenfeld, A. Shabsigh, D. Spratt, Benjamin A. Teply, J. Tward, Dorothy Shead, Deborah A. Freedman-Cass   +31 more
semanticscholar   +1 more source

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

Increased survival with enzalutamide in prostate cancer after chemotherapy.

New England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. de Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. D. de Bono   +19 more
semanticscholar   +1 more source

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells

Cancer Biology & Therapy, 2022
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.
Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino   +10 more
doaj   +1 more source

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

npj Precision Oncology, 2023
Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predict DDR deficiency or treatment benefit ...
Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. Chi, Alexander W. Wyatt   +14 more
doaj   +1 more source

Epidemiology of Prostate Cancer

World Journal of Oncology, 2019
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance ...
Prashanth Rawla
semanticscholar   +1 more source